Introduction
GLICLAGLAZE DAPA 60-10 is a combination diabetes medicine containing Gliclazide SR 60mg and Dapagliflozin 10mg. It is intended for the management of Type 2 Diabetes Mellitus in adults when additional blood glucose control is required under medical supervision.
This combination contains two antidiabetic ingredients that work through different mechanisms. Gliclazide sustained-release (SR) stimulates the pancreas to release insulin, while Dapagliflozin helps the kidneys remove excess glucose through urine. Together, these medicines can support blood sugar management when prescribed as part of an individualized diabetes treatment plan.
Effective diabetes care also involves a balanced diet, regular physical activity, blood glucose monitoring, and routine medical consultations. GLICLAGLAZE DAPA 60-10 should be used only on a healthcare professional’s recommendation.
Uses
Gliclazide SR 60mg and Dapagliflozin 10mg Tablets are primarily used to help manage Type 2 Diabetes Mellitus in suitable adult patients.
The main uses include:
Blood glucose management: Helps lower elevated blood sugar levels through complementary mechanisms.
Fasting blood sugar control: Supports glucose regulation between meals.
Post-meal glucose management: Gliclazide stimulates insulin release, helping the body manage glucose after eating.
Long-term diabetes management: May help improve glycated haemoglobin (HbA1c), an indicator of average blood glucose over approximately three months.
Combination therapy: May be considered when a single medicine does not provide adequate glucose control, depending on the patient's treatment history and clinical needs.
The suitability of this combination depends on factors such as kidney function, existing medicines, blood glucose levels, and the risk of hypoglycaemia.
Benefits
GLICLAGLAZE DAPA 60-10 combines two medicines with complementary actions, offering several potential benefits when appropriately prescribed.
1. Dual-action blood sugar control: Gliclazide encourages insulin secretion, while Dapagliflozin reduces glucose reabsorption in the kidneys, increasing glucose excretion through urine.
2. Support for HbA1c reduction: Improved blood glucose control may help reduce HbA1c levels and support the achievement of individualized diabetes targets.
3. Fasting and post-meal glucose management: The two mechanisms can help address different aspects of elevated blood sugar.
4. Potential weight-management benefits: Dapagliflozin may contribute to modest weight reduction in some patients because glucose is eliminated through urine. Individual results vary.
5. Convenient combination therapy: Combining two active ingredients in one tablet may simplify a prescribed treatment regimen.
6. Broader health considerations: Dapagliflozin has demonstrated heart failure and kidney benefits in specific patient populations. However, these benefits should not automatically be assumed for every patient taking this combination, and the medicine must not be considered a replacement for condition-specific treatment.
Dosage
The dosage of Gliclazide SR 60mg and Dapagliflozin 10mg Tablets must be determined by the prescribing doctor.
Take the tablet exactly as prescribed and follow the recommended timing.
Swallow the sustained-release tablet whole unless the product leaflet specifically permits another method. Do not crush or chew it.
Follow your prescribed meal schedule because Gliclazide can cause low blood sugar, particularly when meals are skipped or delayed.
Monitor blood glucose as advised by your healthcare professional.
If you miss a dose, follow the patient leaflet or ask your pharmacist or doctor. Do not take an extra dose to compensate.
Do not start, stop, or change the dosage independently.
Side Effects
Like other antidiabetic medicines, GLICLAGLAZE DAPA 60-10 may cause side effects. Their occurrence and severity vary between individuals.
Possible side effects include:
Low blood sugar (hypoglycaemia), including sweating, shakiness, hunger, dizziness, or confusion.
Increased urination and thirst.
Dehydration or dizziness, particularly in susceptible patients.
Urinary tract infections.
Genital fungal infections.
Headache, nausea, or gastrointestinal discomfort.
Seek urgent medical attention for severe hypoglycaemia, fainting, serious allergic reactions, or symptoms suggestive of diabetic ketoacidosis, such as persistent nausea, vomiting, abdominal pain, unusual fatigue, or rapid, deep breathing. Ketoacidosis can occasionally occur even when blood glucose is not markedly elevated.
Precautions and Warnings
Before taking GLICLAGLAZE DAPA 60-10, inform your doctor about your medical history and all medicines or supplements you use.
Kidney function: Dapagliflozin's suitability and glucose-lowering effect depend partly on kidney function. Medical assessment and monitoring are important.
Low blood sugar: The risk increases with missed meals, excessive exercise, alcohol, or certain other diabetes medicines.
Dehydration: Maintain appropriate fluid intake, particularly during hot weather or illness, unless your doctor has advised fluid restriction.
Illness and surgery: Vomiting, prolonged fasting, severe illness, or surgery may increase the risk of ketoacidosis. Contact your healthcare team for instructions about temporarily withholding medication.
Pregnancy and breastfeeding: Consult your doctor before use. Alternative treatment may be necessary.
Other conditions: Inform your doctor about liver disease, recurrent urinary or genital infections, low blood pressure, or previous ketoacidosis.
Monitoring: Attend scheduled reviews for blood glucose, HbA1c, kidney function, and other assessments recommended by your clinician.
Conclusion
GLICLAGLAZE DAPA 60-10 contains Gliclazide SR 60mg and Dapagliflozin 10mg, a dual-action combination for managing Type 2 Diabetes Mellitus in appropriately selected adults. Its complementary mechanisms may support blood glucose control and improve HbA1c when combined with healthy lifestyle measures and medical supervision.
For safe and effective treatment, follow your doctor's instructions, monitor blood glucose regularly, understand the warning signs of low blood sugar and ketoacidosis, and attend routine follow-up appointments. This medicine is not suitable for everyone and should be used only when prescribed.
FAQs:
1. What is GLICLAGLAZE DAPA 60-10 used for?
GLICLAGLAZE DAPA 60-10 is a combination of Gliclazide SR 60mg and Dapagliflozin 10mg used to manage Type 2 Diabetes Mellitus in suitable adults when prescribed by a healthcare professional.
2. What is the composition of GLICLAGLAZE DAPA 60-10 tablets?
Each tablet contains Gliclazide SR 60mg and Dapagliflozin 10mg, as specified for this product. Check the product packaging for the complete formulation details.
3. How does Gliclazide SR 60mg and Dapagliflozin 10mg work?
Gliclazide stimulates insulin release from the pancreas, while Dapagliflozin helps the kidneys remove excess glucose through urine. Their complementary actions help lower blood glucose levels.
4. What are the benefits of Gliclazide and Dapagliflozin tablets?
Potential benefits include improved blood glucose control, support for HbA1c reduction, management of fasting and post-meal glucose, and possible modest weight reduction. Results vary between patients.
5. How should GLICLAGLAZE DAPA 60-10 be taken?
Take this medicine exactly as prescribed by your doctor. Follow the recommended timing, do not crush or chew the sustained-release tablet, and do not change the dose without medical advice.
6. What are the common side effects of Gliclazide SR 60mg and Dapagliflozin 10mg?
Possible side effects include low blood sugar, increased urination, thirst, dizziness, dehydration, urinary tract infections, and genital fungal infections. Contact your healthcare professional if symptoms persist or worsen.
7. Can GLICLAGLAZE DAPA 60-10 cause low blood sugar?
Yes. Gliclazide can cause hypoglycaemia, particularly when meals are skipped, alcohol is consumed, or other glucose-lowering medicines are used. Learn to recognise symptoms such as sweating, shaking, hunger, and confusion.
8. Is Gliclazide SR 60mg and Dapagliflozin 10mg suitable for every diabetic patient?
No. Suitability depends on the patient's medical history, kidney function, current medicines, and individual treatment needs. It is not a substitute for professional medical assessment.
9. Can GLICLAGLAZE DAPA 60-10 help with weight management?
Dapagliflozin may contribute to modest weight loss in some patients by increasing glucose excretion through urine. The medicine is prescribed for appropriate medical indications, not solely for weight loss.
